Karger Ralf, Reuter Karoline, Rohlfs Jochen, Nimsky Christopher, Sure Ulrich, Kretschmer Volker
Medizinische Fakultät, Philipps-Universität Marburg, Conradistraße, 35043 Marburg, Germany.
ISRN Hematol. 2012;2012:839242. doi: 10.5402/2012/839242. Epub 2012 Aug 8.
We investigated whether the inclusion of the PFA-100 in the preoperative screening of neurosurgical patients might reduce perioperative bleeding complications. Patients with intracranial space-occupying lesions who were scheduled for neurosurgery underwent routine preoperative PFA-100 testing. In case of an abnormal PFA test, patients received prophylactic treatment with desmopressin. 93 consecutive patients were compared to 102 consecutive patients with comparable characteristics operated before introduction of the PFA-100 testing. 2 patients (2.2%) in the PFA group and 2 patients (2.0%) in the non-PFA group experienced clinically relevant intracranial bleeding confirmed by computed tomography (OR 1.05, 95% CI 0.39-2.82; P = 1.0). Transfusions were not significantly different between the two groups. 13 (14.0%) patients in the PFA group and 5 (4.9%) patients in the non-PFA group received desmopressin (OR 3.2, 95% CI 1.1-9.2; P = 0.045). Preoperative screening with the PFA-100 did result in a significant increase in the administration of desmopressin, which could not reduce perioperative bleeding complications or transfusions.
我们研究了在神经外科手术患者的术前筛查中加入血小板功能分析仪-100(PFA-100)是否可以减少围手术期出血并发症。计划进行神经外科手术的颅内占位性病变患者接受了常规术前PFA-100检测。若PFA检测结果异常,患者接受去氨加压素预防性治疗。将连续93例患者与在引入PFA-100检测之前接受手术的102例具有可比特征的连续患者进行比较。PFA组中有2例患者(2.2%),非PFA组中有2例患者(2.0%)发生了经计算机断层扫描确认的具有临床意义的颅内出血(比值比1.05,95%可信区间0.39-2.82;P = 1.0)。两组之间的输血情况无显著差异。PFA组中有13例患者(14.0%),非PFA组中有5例患者(4.9%)接受了去氨加压素治疗(比值比3.2,95%可信区间1.1-9.2;P = 0.045)。使用PFA-100进行术前筛查确实导致去氨加压素的使用显著增加,但这并不能减少围手术期出血并发症或输血情况。